The next generation biopharmaceuticals

Executive Management Team

David Bejker, M.Sc. Chief Executive Officer

Mr. Bejker has experience from the biotech industry both as an investor and as a business developer. Most recently he worked at HealthCap, a family of multi stage venture capital funds. Bejker has previously worked with business development at Affibody. Mr. Bejker holds a M.Sc. in Business and Economics from the Stockholm School of Economics, where he was awarded the Karl-Adam Bonnier Scholarship to Darden Graduate Business School, Charlotteville, Virginia.

Karin Nord, Ph.D. SVP Research Operations

Dr. Nord is one of the co-founders of Affibody and was one of the first employees; she had an important role in the establishment of the company in 1998. Dr. Nord received her Ph.D., which included pioneering work on Affibody® molecules, from the Royal Institute of Technology in Stockholm in 1999. Dr. Nord was the lead author of the first report on Affibody® molecules, published in Nature Biotechnology in 1997.

Fredrik Frejd, Ph.D., Prof. CSO

Prof. Frejd has over fifteen years of experience in life science research with particular expertise in tumor biology, phage display and therapeutic protein engineering of antibody fragments and alternative scaffolds. He joined Affibody AB in 2002. Dr. Frejd is an adjunct professor at the unit for Biomedical radiation sciences, Uppsala University.

Nikolai Brun, Ph.D., Prof. CMO

Dr. Brun has ~20 years experience in life science industry with with particular expertise in clinical drug development, Regulatory affairs, Medical Affairs. His most recent position was  on the leadership team of Danish Medicines Agency.

Camilla Danell CFO

Ms. Danell has ~20 years of senior finance roles in public listed groups and private companies in an international environment. She has experience from several international improvement projects, ERP projects and IPO preparations and was an auditor for 11 years.

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

  • Interim Report January to March 2020 (May 15, 2020)
  • Interim Report January to June 2020 (August 21, 2020)
  • Interim Report January to September 2020 (November 13, 2020)
  • Year End Report 2020 (February 2021)